News | December 05, 2006

U.S. Should Merge Anemia Drug, Dialysis Costs: Report

Medicare, the U.S. insurance program for elderly and disabled Americans, should lump the price of anemia drugs with overall payments for kidney dialysis services to improve efficiency and contain costs, according to a government report released on Tuesday.

Medicare's method of paying separately for anemia drugs, primarily Amgen Inc.'s Epogen, and for dialysis services is a concern as use grows, the Government Accountability Office (GAO) said. Medicare covers about 43 million Americans and spent $2 billion on Epogen in 2005.

The report by the investigative arm of Congress was released ahead of a U.S. House of Representatives Ways and Means Committee hearing on Wednesday to discuss use of the drugs and growing government spending on dialysis patients.

Medicare has taken steps over the years to address its payment policy for kidney disease treatment, but lawmakers may need to intervene, the GAO said.

"The Congress should consider establishing a bundled payment system for all (end-stage renal disease) services, including drugs, as soon as possible," the GAO said.

Analysts have said they do not expect any major changes in reimbursement after the hearing. Still, attempts to curb Medicare payments could cause investor unease over Amgen, which gets nearly half its revenue from sales of two anemia drugs.

Critics have said the Medicare price structure drives up use of the drugs, and the program does not limit the dose doctors can administer with government reimbursement. Recent studies also linked higher doses of anemia drugs with heart-related complications.

Industry analysts have said bundling anemia drug reimbursement with dialysis payments would remove the profit incentive for doctors to use the drugs.

Currently, the U.S. Medicare program reimburses dialysis providers for Amgen's Epogen at the average sales price (ASP) plus a 6 percent premium. Under that formula, the higher a drug is priced, the more money doctors make.

"The ASP method relies on market forces to moderate manufacturers' prices, however, Epogen is the product of a single manufacturer and has no competitor products," the GAO said.

Medicare bundles drug prices with other costs for most other types of therapies it covers.

Separately, Centers for Medicare and Medicaid Services Acting Administrator Leslie Norwalk said the agency agreed such reforms would help promote efficiency and flexibility for dialysis centers.

Amgen's Aranesp, a longer lasting anemia drug, is not generally marketed to dialysis clinics, according to the GAO. Johnson and Johnson's Procrit drug also treats anemia in kidney patients but is not approved for those not on dialysis.

Shares of Amgen fell as much as 3 percent when news of the GAO report trickled out on Friday. They closed down 9 cents, or less than 1 percent on Tuesday after the report's release.

Related Content

Hospital for Special Surgery Invests in Sectra Orthopedic 3-D Planning Software
News | Orthopedic Imaging | January 18, 2018
January 18, 2018 – International medical imaging IT and cybersecurity company Sectra announces that Hospital for Spec
Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
Fat Distribution in Women and Men Provides Clues to Heart Attack Risk
News | Women's Health | January 11, 2018
January 11, 2018 – It’s not the amount of fat in your body but where it is stored that may increase your risk for hea
Minimally Invasive Treatment Provides Relief from Back Pain

Lumbar spine MRI showing disc herniation and nerve root at baseline and one month after treatment

News | Interventional Radiology | January 11, 2018
The majority of patients were pain free after receiving a new image-guided pulsed radiofrequency treatment for low back...
Emergency Radiologists See Inner Toll of Opioid Use Disorders

Rates of Imaging Positivity for IV-SUDs Complications. Image courtesy of Efren J. Flores, M.D.

News | Clinical Study | January 11, 2018
January 11, 2018 – Emergency radiologists are seeing a high prevalence of patients with complications related to opio
CT Shows Enlarged Aortas in Former Pro Football Players

3-D rendering from a cardiac CT dataset demonstrating mild dilation of the ascending aorta.

News | Computed Tomography (CT) | January 11, 2018
Former National Football League (NFL) players are more likely to have enlarged aortas, a condition that may put them at...

Size comparison between 3-D printed prosthesis implant and a penny.

News | 3-D Printing | January 11, 2018
January 11, 2018 — Researchers using...
BlueCross BlueShield Companies in Eight States Issue Positive Medical Policies for HeartFlow FFRct Analysis
News | CT Angiography (CTA) | December 28, 2017
HeartFlow Inc. announced that Health Care Service Corp. (HCSC), which operates Blue Cross and Blue Shield plans in five...
Artificial intelligence was the number one topic in radiology in 2017.

Artificial intelligence was the number one topic of interest in radiology in 2017, based on the most popular articles and videos on ITN in 2017.

Feature | Imaging | December 28, 2017
The Imaging Technology News (ITN) website had another record year with more than 1.25 million page views in 2017.
Median Technologies Collaborating With Chinese Hospital for Lung Cancer Screening Programs. Dave Fornell
News | Lung Cancer | December 22, 2017
Median Technologies recently announced a research collaboration agreement with Xingtai People's Hospital, Xingtai City...
Overlay Init